Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07548476 · ClinicalTrials.gov registry record · NA

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

A NA study, sponsored by Dana-Farber Cancer Institute.

Not yet
Registry status
NA
Development phase
50
Enrollment target

NCT07548476: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.

NCT07548476 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07548476, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.

NOT YET RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The names of the two study groups in this research study are: * Acupuncture + Virtual Exercise (AVE) * Virtual Exercise Only (VE)

Primary Outcome

NPS is a multidimensional tool that uses a self-report numerical rating scale (0-10) to quantify global pain intensity, unpleasantness, and eight additional descriptive qualities of neuropathic pain, Scores on each 0-10 scale are patient-reported, with higher scores indicating greater pain intensity or unpleasantness. In addition, the NPS includes one semi-structured question that assesses the temporal sequence of pain.

Interventions

  • BEHAVIORAL Exercise
  • PROCEDURE Acupuncture

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-10-02
Est. Completion 2027-03-02
Phase NA
Dana-Farber Cancer Institute

781 total trials

What is known before NCT07548476 opens enrollment

NCT07548476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Exercise is the first listed.

NCT07548476 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07548476 about?

NCT07548476 is a clinical study titled "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy". The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizuma...

What is the current status of trial NCT07548476?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-10-02. Estimated completion is 2027-03-02.

What interventions are being tested in trial NCT07548476?

The interventions under investigation include: Exercise (BEHAVIORAL), Acupuncture (PROCEDURE).

Who is sponsoring clinical trial NCT07548476?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07548476's enrollment target sits among peer trials

50 1279th of 2000 higher than 622 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07548476, the US trial registry maintained by the National Library of Medicine. NCT07548476 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.